EUVIMEDEUVIMED entdecken
Crossref

A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma

Tongyu Li, Wanchuan Zhuang, Shufang Fan, Ping Yi, Lixia Sheng, Wenbin Qian, Guifang Ouyang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Tongyu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Road, Ningbo, Zhejiang 315010, China. Hauptthemen laut MEDLINE: Prodrugs, Reactive Oxygen Species, Lymphoma, Vorinostat. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Ningbo Municipality, Natural Science Foundation of Zhejiang Province, Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical utility of histone deacetylase inhibitors (HDACi) like vorinostat (SAHA) in lymphoma is constrained by poor pharmacokinetics and off-target toxicity. To address this, we developed a reactive oxygen species (ROS)-responsive homodimeric SAHA prodrug (SAHA-tk-SAHA) linked via a thioketal bridge, which self-assembled into PEGylated nanoparticles (tk-diSAHA NP). These monodisperse nanoparticles (119.3 ± 4.0 nm) demonstrated excellent stability and ROS-triggered drug release (68.18 ± 2.25% with 10 mM H2O2 vs 6.24% in PBS over 48 h). In vitro, tk-diSAHA NP induced G0/G1 cell cycle arrest and apoptosis in lymphoma cells. In A20 lymphoma-bearing mice, intravenous tk-diSAHA NP achieved superior tumor growth inhibition (615.18 ± 147.88 mm3) compared to oral SAHA (1134.78 ± 311.31 mm3, p < 0.05), with enhanced histone H3 acetylation in tumors and no appreciable systemic toxicity. This ROS-activatable nanoprodrug platform presents a promising strategy to enhance the efficacy and safety of HDACi-based epigenetic therapy for lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsReactive Oxygen SpeciesLymphomaVorinostatNanoparticlesEpigenesis, GeneticHistone Deacetylase InhibitorsAntineoplastic AgentsAnimalsHumansMiceApoptosisCell Line, Tumor

Substanzen

ProdrugsReactive Oxygen SpeciesVorinostatHistone Deacetylase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Road, Ningbo, Zhejiang 315010, China.
  • Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
  • Department of Hematology, Lianyungang Second People's Hospital, Lianyungang, Jiangsu 222000, China.
  • Department of Research, Wuhan Kindstar Medical Laboratory Co. Ltd., 666 Gaoxin Avenue, Wuhan, Hubei 430060, China.

ORCID-Profile: Guifang Ouyang

Förderung

  • Natural Science Foundation of Ningbo Municipality
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project

Zitieren

APA

Li, T., Zhuang, W., Fan, S., Yi, P., Sheng, L., Qian, W., & Ouyang, G. (2026). A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02897

Vancouver

Li T, Zhuang W, Fan S, Yi P, Sheng L, Qian W, et al. A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02897

BibTeX
@article{Li2026,
  author = {Li, Tongyu and Zhuang, Wanchuan and Fan, Shufang and Yi, Ping and Sheng, Lixia and Qian, Wenbin and Ouyang, Guifang},
  title = {A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02897}
}
Kostenlos starten →